TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 732 Thousand USD | -24.46% |
| 2022 | 969 Thousand USD | -16.97% |
| 2021 | 1.16 Million USD | -16.1% |
| 2020 | 1.39 Million USD | -49.22% |
| 2019 | 2.73 Million USD | -48.74% |
| 2018 | 5.34 Million USD | 16.08% |
| 2017 | 4.6 Million USD | -35.44% |
| 2016 | 7.13 Million USD | -4.47% |
| 2015 | 7.46 Million USD | 75.29% |
| 2014 | 4.25 Million USD | 141.38% |
| 2013 | 1.76 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 FY | 732 Thousand USD | -24.46% |
| 2023 Q2 | 700 Thousand USD | 16.67% |
| 2023 Q4 | 732 Thousand USD | 4.57% |
| 2023 Q3 | 700 Thousand USD | 0.0% |
| 2023 Q1 | 600 Thousand USD | -38.08% |
| 2022 FY | 969 Thousand USD | -16.97% |
| 2022 Q2 | 600 Thousand USD | 0.0% |
| 2022 Q1 | 600 Thousand USD | -48.59% |
| 2022 Q4 | 969 Thousand USD | -89.35% |
| 2022 Q3 | 9.09 Million USD | 1415.83% |
| 2021 Q2 | - USD | -100.0% |
| 2021 Q1 | 698 Thousand USD | -49.82% |
| 2021 FY | 1.16 Million USD | -16.1% |
| 2021 Q4 | 1.16 Million USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q2 | 2.76 Million USD | -19.69% |
| 2020 Q1 | 3.43 Million USD | 25.52% |
| 2020 Q4 | 1.39 Million USD | -33.09% |
| 2020 FY | 1.39 Million USD | -49.22% |
| 2020 Q3 | 2.07 Million USD | -24.7% |
| 2019 FY | 2.73 Million USD | -48.74% |
| 2019 Q2 | 4.05 Million USD | -13.75% |
| 2019 Q3 | 3.4 Million USD | -16.14% |
| 2019 Q4 | 2.73 Million USD | -19.49% |
| 2019 Q1 | 4.7 Million USD | -11.96% |
| 2018 FY | 5.34 Million USD | 16.08% |
| 2018 Q4 | 5.34 Million USD | -10.55% |
| 2018 Q3 | 5.97 Million USD | -4.55% |
| 2018 Q2 | 6.25 Million USD | 0.72% |
| 2018 Q1 | 6.21 Million USD | 34.98% |
| 2017 Q2 | 6.04 Million USD | -10.43% |
| 2017 FY | 4.6 Million USD | -35.44% |
| 2017 Q1 | 6.74 Million USD | -5.37% |
| 2017 Q4 | 4.6 Million USD | -13.62% |
| 2017 Q3 | 5.32 Million USD | -11.82% |
| 2016 Q1 | 6.58 Million USD | -11.76% |
| 2016 FY | 7.13 Million USD | -4.47% |
| 2016 Q4 | 7.13 Million USD | 48.98% |
| 2016 Q3 | 4.78 Million USD | -15.95% |
| 2016 Q2 | 5.69 Million USD | -13.54% |
| 2015 Q2 | 6.81 Million USD | 123.86% |
| 2015 FY | 7.46 Million USD | 75.29% |
| 2015 Q3 | 6.6 Million USD | -3.1% |
| 2015 Q4 | 7.46 Million USD | 13.07% |
| 2015 Q1 | 3.04 Million USD | -28.53% |
| 2014 FY | 4.25 Million USD | 141.38% |
| 2014 Q3 | 5.45 Million USD | 12.75% |
| 2014 Q4 | 4.25 Million USD | -21.94% |
| 2014 Q2 | 4.83 Million USD | 223.18% |
| 2014 Q1 | 1.49 Million USD | -15.14% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 1.76 Million USD | 0.0% |
| 2013 Q4 | 1.76 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | 34.825% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 43.344% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 98.326% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -7220.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | 92.926% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -438.235% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -508.469% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 91.578% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 98.502% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 80.447% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 97.423% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.515% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -234.248% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 19.693% |
| Molecular Templates, Inc. | 9.74 Million USD | 92.486% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 60.891% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 96.161% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 82.546% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.298% |
| Statera Biopharma, Inc. | 11.43 Million USD | 93.596% |
| Trevena, Inc. | 35.23 Million USD | 97.922% |
| Vaxxinity, Inc. | 13.26 Million USD | 94.48% |
| Vaccinex, Inc. | 26 Thousand USD | -2715.385% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |